ReviewMelanoma management2020
Melanoma in pregnancy: certainties unborn.
Review in Melanoma management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- In situ and localized primary invasive pregnancy-associated melanoma: Maternal and perinatal outcomes.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Pregnancy Associated Melanoma: Diagnostic and Therapeutic Challenges.Medicina (Kaunas, Lithuania) · 2026Review
- Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations.Advances in therapy · 2026Review
- When two lives intersect: melanoma in pregnancy: mechanisms, risks, and management strategies.Contemporary oncology (Poznan, Poland) · 2026Review
- Melanoma in pregnancy: multidisciplinary treatment management and outcome.Dermatology reports · 2025Article
- Melanoma in Pregnancy-Diagnosis, Treatment, and Consequences for Fetal Development and the Maintenance of Pregnancy.Cancers · 2024Review
- Fetal and placental metastases associated with maternal cancers.Abdominal radiology (New York) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma diagnosed during childbearing period or up to 1 year after delivery is defined as pregnancy-associated melanoma (PAM). There is some evidence that PAM has worse prognosis if compared with melanoma in nonpregnant women, although literature is still inconclusive. Many biological mechanisms could explain this behavior, such as hormonal and immune status, increased lymphangiogenesis but also delay in diagnostic and therapeutic management. If PAM is suspected, a prompt excisional biopsy under local anesthesia can be performed regardless of the gestational period. Conversely, additional staging procedures (such as sentinel lymph node biopsy or imaging) and systemic therapy are still debatable during pregnancy. A multidisciplinary tailored approach should be preferred, together with exhaustive counseling of the mother.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.